TY - JOUR
T1 - Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma
AU - Klatte, Tobias
AU - Rao, P. Nagesh
AU - De Martino, Michela
AU - Larochelle, Jeffrey
AU - Shuch, Brian
AU - Zomorodian, Nazy
AU - Said, Jonathan
AU - Kabbinavar, Fairooz F.
AU - Belldegrun, Arie S.
AU - Pantuck, Allan J.
PY - 2009/2/10
Y1 - 2009/2/10
N2 - Purpose The majority of cytogenetic studies in renal cell carcinoma (RCC) have been impaired by small sample size, retrospective character, and lack of a survival end point. We prospectively studied the prognostic impact of cytogenetic abnormalities on a larger cohort of patients having up to 108 months of follow-up. Patients and Methods Tumors of 282 patients who underwent nephrectomy for clear cell RCC were cytogenetically analyzed. Results were correlated with pathological factors and disease-specific survival. Results The most frequently observed cytogenetic abnormalities were loss of 3p (60%), gain of 5q (33%), loss of 14q (28%), trisomy 7 (26%), loss of 8p (20%), loss of 6q (17%), loss of 9p (16%), loss of 4p (13%), and loss of chromosome Y in men (55%). Tumors with loss of 3p presented at lower TNM stages. Loss of 4p, 9p, and 14q were all associated with higher TNM stages, higher grade, and greater tumor size. A deletion of 3p was associated with better prognosis (P = .03), while loss of 4p (P < .001), loss of 9p (P < .01), and loss of 14q (P < .01) were each associated with worse prognosis. Loss of the Y chromosome led to improved progression-free survival in metastatic patients (P = .02). In multivariate analysis, loss of 9p was retained as an independent prognostic factor. Conclusion This cytogenetic study serves as a proof of principal that genetic information, such as loss of chromosome 9, can be obtained from widely available technology, and can provide additional prognostic information to standard clinicopathologic variables.
AB - Purpose The majority of cytogenetic studies in renal cell carcinoma (RCC) have been impaired by small sample size, retrospective character, and lack of a survival end point. We prospectively studied the prognostic impact of cytogenetic abnormalities on a larger cohort of patients having up to 108 months of follow-up. Patients and Methods Tumors of 282 patients who underwent nephrectomy for clear cell RCC were cytogenetically analyzed. Results were correlated with pathological factors and disease-specific survival. Results The most frequently observed cytogenetic abnormalities were loss of 3p (60%), gain of 5q (33%), loss of 14q (28%), trisomy 7 (26%), loss of 8p (20%), loss of 6q (17%), loss of 9p (16%), loss of 4p (13%), and loss of chromosome Y in men (55%). Tumors with loss of 3p presented at lower TNM stages. Loss of 4p, 9p, and 14q were all associated with higher TNM stages, higher grade, and greater tumor size. A deletion of 3p was associated with better prognosis (P = .03), while loss of 4p (P < .001), loss of 9p (P < .01), and loss of 14q (P < .01) were each associated with worse prognosis. Loss of the Y chromosome led to improved progression-free survival in metastatic patients (P = .02). In multivariate analysis, loss of 9p was retained as an independent prognostic factor. Conclusion This cytogenetic study serves as a proof of principal that genetic information, such as loss of chromosome 9, can be obtained from widely available technology, and can provide additional prognostic information to standard clinicopathologic variables.
UR - http://www.scopus.com/inward/record.url?scp=59949102663&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=59949102663&partnerID=8YFLogxK
U2 - 10.1200/JCO.2007.15.8345
DO - 10.1200/JCO.2007.15.8345
M3 - Article
C2 - 19124809
AN - SCOPUS:59949102663
SN - 0732-183X
VL - 27
SP - 746
EP - 753
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 5
ER -